期刊
VIRUS RESEARCH
卷 180, 期 -, 页码 23-30出版社
ELSEVIER
DOI: 10.1016/j.virusres.2013.12.002
关键词
African horse sickness; Vaccinia; MVA-VP2; Protection; Humoral response; Passive immunisation
类别
资金
- DEFRA [SE4109, AGL2011-23506/GAN]
- BBSRC [BBS/E/I/00001446, BB/H531151/1, BB/D014204/1, BBS/E/I/00001455, BB/I017259/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/D014204/1, BBS/E/I/00001446, BB/I017259/1, BBS/E/I/00001455, BB/H531151/1] Funding Source: researchfish
In previous studies we showed that a recombinant Modified Vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR-/-) against challenge. We continued these studies and determined, in the IFNAR-/- mouse model, whether the antibody responses induced by MVA-VP2 vaccination play a key role in protection against AHSV. Thus, groups of mice were vaccinated with wild type MVA (MVA-wt) or MVA-VP2 and the antisera from these mice were used in a passive immunisation experiment. Donor antisera from (a) MVA-wt; (b) MVA-VP2 vaccinated; or (c) MVA-VP2 vaccinated and AHSV infected mice, were transferred to AHSV non-immune recipient mice. The recipients were challenged with virulent AHSV together with MVA-VP2 vaccinated and MVA-wt vaccinated control animals and the levels of protection against AHSV-4 were compared between all these groups. The results showed that following AHSV challenge, mice that were passively immunised with MVA-VP2 vaccinated antisera were highly protected against AHSV disease and had lower levels of viraemia than recipients of MVA-wt antisera. Our study indicates that MVA-VP2 vaccination induces a highly protective humoral immune response against AHSV. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据